These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 31077069)

  • 1. Predictive Value of ERCC1, ERCC2, and XRCC Expression for Patients with Locally Advanced or Metastatic Gastric Cancer Treated with Neoadjuvant mFOLFOX-4 Chemotherapy.
    Yeh YS; Chen YT; Tsai HL; Huang CW; Ma CJ; Su WC; Huang CM; Huang MY; Hu HM; Lu CY; Wang JY
    Pathol Oncol Res; 2020 Apr; 26(2):1105-1116. PubMed ID: 31077069
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive value of ERCC1, ERCC2, and XRCC1 overexpression for stage III colorectal cancer patients receiving FOLFOX-4 adjuvant chemotherapy.
    Huang MY; Tsai HL; Lin CH; Huang CW; Ma CJ; Huang CM; Chai CY; Wang JY
    J Surg Oncol; 2013 Dec; 108(7):457-64. PubMed ID: 23996617
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship Between Expression of Proteins ERCC1, ERCC2, and XRCC1 and Clinical Outcomes in Patients with Rectal Cancer Treated with FOLFOX-Based Preoperative Chemoradiotherapy.
    Huang MY; Huang JJ; Huang CM; Lin CH; Tsai HL; Huang CW; Chai CY; Lin CY; Wang JY
    World J Surg; 2017 Nov; 41(11):2884-2897. PubMed ID: 28608017
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ERCC1 and ERCC2 as predictive biomarkers to oxaliplatin-based chemotherapy in colorectal cancer patients from Egypt.
    Kassem AB; Salem SE; Abdelrahim ME; Said AS; Salahuddin A; Hussein MM; Bahnassy AA
    Exp Mol Pathol; 2017 Feb; 102(1):78-85. PubMed ID: 28088319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic variability of DNA repair mechanisms influences chemotherapy outcome of gastric cancer.
    Yu H; Wu X; Zhang Y; Jin Z; Li G; Zhao H
    Int J Clin Exp Pathol; 2015; 8(4):4106-12. PubMed ID: 26097599
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer.
    Kwon HC; Roh MS; Oh SY; Kim SH; Kim MC; Kim JS; Kim HJ
    Ann Oncol; 2007 Mar; 18(3):504-9. PubMed ID: 17322540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of DNA repair gene variants with colorectal cancer: risk, toxicity, and survival.
    Salimzadeh H; Lindskog EB; Gustavsson B; Wettergren Y; Ljungman D
    BMC Cancer; 2020 May; 20(1):409. PubMed ID: 32397974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlations between microsatellite instability, ERCC1/XRCC1 polymorphism and clinical characteristics, and FOLFOX adjuvant chemotherapy effect of colorectal cancer patients.
    Zhang L; Zhao J; Yu B; Song X; Sun G; Han L; Wang L; Dong S
    Cancer Genet; 2017 Dec; 218-219():51-57. PubMed ID: 29153096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined effect of ERCC1 and ERCC2 polymorphisms on overall survival in non-squamous non-small-cell lung cancer patients treated with first-line pemetrexed/platinum.
    Liao WY; Ho CC; Tsai TH; Chen KY; Shih JY; Yu CJ
    Lung Cancer; 2018 Apr; 118():90-96. PubMed ID: 29572009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Excision repair cross-complementation group 1 codon 118 polymorphism, micro ribonucleic acid and protein expression, clinical outcome of the advanced gastric cancer response to first-line FOLFOX-4 in Qinghai-Tibetan plateau population.
    Qi YJ; Cui S; Yang YZ; Han JQ; Cai BJ; Sheng CF; Ma Y; Wuren T; Ge RL
    J Cancer Res Ther; 2013; 9(3):410-5. PubMed ID: 24125975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ERCC1 and XPD/ERCC2 polymorphisms' predictive value of oxaliplatin-based chemotherapies in advanced colorectal cancer has an ethnic discrepancy: a meta-analysis.
    Lu X; Xiao S; Jin C; van der Straaten T; Li X
    J Clin Lab Anal; 2012 Jan; 26(1):10-5. PubMed ID: 24833529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influences of ERCC1, ERCC2, XRCC1, GSTP1, GSTT1, and MTHFR polymorphisms on clinical outcomes in gastric cancer patients treated with EOF chemotherapy.
    Liu R; Zhao X; Liu X; Chen Z; Qiu L; Geng R; Guo W; He G; Yin J; Li J; Zhu X
    Tumour Biol; 2016 Feb; 37(2):1753-62. PubMed ID: 26314858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GSTP1, ERCC1 and ERCC2 polymorphisms, expression and clinical outcome of oxaliplatin-based adjuvant chemotherapy in colorectal cancer in Chinese population.
    Li HY; Ge X; Huang GM; Li KY; Zhao JQ; Yu XM; Bi WS; Wang YL
    Asian Pac J Cancer Prev; 2012; 13(7):3465-9. PubMed ID: 22994779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ERCC1 expression affects outcome in metastatic pancreatic carcinoma treated with FOLFIRINOX: A single institution analysis.
    Strippoli A; Rossi S; Martini M; Basso M; D'Argento E; Schinzari G; Barile R; Cassano A; Barone C
    Oncotarget; 2016 Jun; 7(23):35159-68. PubMed ID: 27147577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Higher Expression of ERCC1 May Be Associated with Resistance to Adjuvant Platinum-Based Chemotherapy in Gastric Cancer.
    Wan J; Chao L; Lee AC; Chen Q
    Cancer Invest; 2017 Feb; 35(2):85-91. PubMed ID: 28102711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of ERCC1 and ERCC2 gene polymorphisms in patients with gastric cancer receiving platinum-based chemotherapy.
    Mo J; Luo M; Cui J; Zhou S
    Int J Clin Exp Pathol; 2015; 8(11):15065-71. PubMed ID: 26823845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II study of neoadjuvant combination chemotherapy with docetaxel, cisplatin, and S-1 for locally advanced resectable gastric cancer: nucleotide excision repair (NER) as potential chemoresistance marker.
    Hirakawa M; Sato Y; Ohnuma H; Takayama T; Sagawa T; Nobuoka T; Harada K; Miyamoto H; Sato Y; Takahashi Y; Katsuki S; Hirayama M; Takahashi M; Ono M; Maeda M; Takada K; Hayashi T; Sato T; Miyanishi K; Takimoto R; Kobune M; Hirata K; Kato J
    Cancer Chemother Pharmacol; 2013 Mar; 71(3):789-97. PubMed ID: 23338051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene polymorphisms predict toxicity to neoadjuvant therapy in patients with rectal cancer.
    Duldulao MP; Lee W; Nelson RA; Ho J; Le M; Chen Z; Li W; Kim J; Garcia-Aguilar J
    Cancer; 2013 Mar; 119(5):1106-12. PubMed ID: 23096768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of ERCC1 and ERCC4 polymorphisms on response to prognosis in gastric cancer treated with FOLFOX-based chemotherapy.
    Lu ZM; Luo TH; Nie MM; Fang GE; Ma LY; Xue XC; Wei G; Ke CW; Bi JW
    Tumour Biol; 2014 Apr; 35(4):2941-8. PubMed ID: 24318989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ERCC1 RNA expression in peripheral blood predicts minor histopathological response to neoadjuvant radio-chemotherapy in patients with locally advanced cancer of the esophagus.
    Brabender J; Vallböhmer D; Grimminger P; Hoffmann AC; Ling F; Lurje G; Bollschweiler E; Schneider PM; Hölscher AH; Metzger R
    J Gastrointest Surg; 2008 Nov; 12(11):1815-21. PubMed ID: 18769985
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.